Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

Author:

O’Shaughnessy JoyceORCID,Petrakova Katarina,Sonke Gabe S.,Conte Pierfranco,Arteaga Carlos L.,Cameron David A.,Hart Lowell L.,Villanueva Cristian,Jakobsen Erik,Beck Joseph T.,Lindquist Deborah,Souami Farida,Mondal Shoubhik,Germa Caroline,Hortobagyi Gabriel N.

Funder

The study was initiated, funded, and sponsored by Novartis Pharmaceuticals Corporation.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Reference25 articles.

1. International Agency for Research on Cancer (2012) GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Default.aspx . Accessed 11 July 2017

2. Hosford SR, Miller TW (2014) Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenom Pers Med 7:203–215

3. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29

4. Miao H, Hartman M, Bhoo-Pathy N et al (2014) Predicting survival of de novo metastatic breast cancer in Asian women: systematic review and validation study. PLOS ONE 9:e93755

5. Cardoso F, Costa A, Senkus E et al (2017) 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol 28:16–33

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3